Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jankovic, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jankovic, J.
NEUROLOGY 1983;33:505
© 1983 American Academy of Neurology

Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy

Joseph Jankovic, MD

From the Department of Neurology, Baylor College of Medicine, Texas Medical Center, Houston, TX.

We evaluated pergolide in 22 patients with Parkinson's disease and 3 with progressive supranuclear palsy (PSP). After achieving an optimal dose of pergolide and Sinemet, a matching placebo was substituted in double-blind manner. The mean dose of levodopa (in Sinemet) was reduced by 68%; in eight patients, pergolide completely replaced levodopa. In parkinsonian patients, the mean Hoehn-Yahr stage decreased from 3.2 to 1.6, and the mean total disability score decreased from 48.3 to 17.8. In 10 patients with on-off phenomenon, the time on increased 174% with pergolide. There was little effect in PSP. Postural light-headedness and reversible mental changes were seen.

Address correspondence and reprint requests to Dr. Jankovic, Department of Neurology, Baylor College of Medicine, Texas Medical Center, Houston, TX 77030.

Presented at the thirty-fourth annual meeting of the American Academy of Neurology, Washington, DC, April 1982.

Accepted for publication July 26, 1982.




This article has been cited by other articles:


Home page
Arch NeurolHome page
K. Kompoliti, C. G. Goetz, I. Litvan, K. Jellinger, and M. Verny
Pharmacological Therapy in Progressive Supranuclear Palsy
Arch Neurol, August 1, 1998; 55(8): 1099 - 1102.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1983 by AAN Enterprises, Inc.